Representative Publications

(20 out of 380 peer-reviewed English papers)

As of June 1st, 2017

Akira Nakagawara, MD, PhD

1. **Nakagawara, A.**, Nathan, C.F., Cohn, Z.A. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. ***J. Clin. Invest.*** 68:1243-1252, 1981.

2. **Nakagawara, A.**, De Santis, N.M., Nogueira, N., Nathan, C.F. Lymphokines enhance the capacity of human monocytes to secrete reactive oxygen intermediates. ***J. Clin. Invest***. 70:1042-1048, 1982.

3. **Nakagawara, A.**,, Ikeda, K. N-myc oncogene amplification and catecholamine metabolism in children with neuroblastoma. ***Lancet,*** 1:559, 1987.

4. **Nakagawara, A.**, Arima-Nakagawara, M., Scavarda, N.J., Azar, C.G., Cantor, A.B., Brodeur, G.M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. ***N. Engl. J. Med***. 328:847-854, 1993.

5. **Nakagawara, A.**, Azar, C.G., Scavarda, N.J., Brodeur, G.M. Expression and function of TRK-B and BDNF in human neuroblastomas. ***Mol. Cell. Biol.*** 14:759-767, 1994.

6. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh I., Ikawa, Y., Nimura, Y., **Nakagawara, A.,** Obinata, M., Ikawa, S. Cloning and functional analysis of human p51, structurally and functionally resembling p53. ***Nat. Med.*** 4:839-843, 1998.

7. Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Todo S, Mizuguchi H, Hayakawa T, **Nakagawara A**. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through p73-specific target element within the ΔNp73 promoter. ***Mol. Cell. Biol.*** 22: 2575-2585, 2002.

8. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, **Nakagawara A**. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. ***J. Biol. Chem.*** 279:25549-25561. 2004.

9. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S, Yoshida Y, Fuchioka M, Ishii S, **Nakagawara A**. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate-risk neuroblastomas. ***Cancer Cell*** 7:337-350, 2005

10. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, **Nakagawara A**. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. ***Oncogene*** 27:441-449, 2008

11. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Soda M, Kikuchi A, Igarashi T, **Nakagawara A**, Hayashi Y, Mano H, Ogawa S. Novel oncogenic mutations of ALK kinase in neuroblastoma. ***Nature*** 455:971-974, 2008.

12. Suenaga Y, Ozaki T, Tanaka Y, Bu Y, Kamijo T, Suzuki M, Kimura H, Tokuhisa T, **Nakagawara A***, Tamura T*. TATA-binding protein (TBP)-like protein is engaged in etoposide-induced apoptosis through transcriptional activation of human *TAp63* gene. ***J. Biol. Chem*.** 284:35433-35440, 2009

13. Munirajan AK, Ando K, Mukai A, Takahashi M, Suenaga Y, Ohira M, Koda T, Hirota T, Ozaki T, **Nakagawara A**. KIF1Bβ functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. ***J. Biol. Chem.*** 283:24426-24434. 2008

14. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Okoshi R, Kageyama H, Kimura H, Miyazaki M, Ito Y, **Nakagawara A**. RUNX3 contributes to the regulation of DNA damage response and acts as a co-activator for tumor suppressor p53. ***J. Biol. Chem.*** 285:16693-16703, 2010

15. Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, **Nakagawara A**, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. ***J. Clin. Oncol*.** 29:4358-4364, 2011

16. Yamaki T, Suenaga Y, Toshihiko Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, **Nakagawara A**. Temozolomide suppresses *MYC* via activation of TAp63 to inhibit progression of human glioblastoma. ***Scientific Report*** 3:1160, 2013

17. Zhu Y, Li Y, Haraguchi S, Yu M, Ohira M, Ozaki T, Nakagawa A, Ushijima T, Isogai E, Koseki H, Nakamura Y, Kong C, Mehlen P, Arakawa H, **Nakagawara A**. Dependence receptor UNC5D mediates nerve growth factor depletion-induced neruoblastoma regression. ***J. Clin. Invest.*** 123:2935-2947, 2013

18. Suenaga Y, Islam SMR, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibta T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, **Nakagawara A**. NCYM, a cis-antisense gene of MYCN, encodes a de novo evoluted protein that inhibits GSK3b resulting in the stabilization of MYCN in human neuroblastoma. ***PLoS Genet.*** 2014 Jan;10(1):e1003996 doi:n10.1371/journal.pgen.1003996

19. Satoh S, Takatori A, Ogura A, Kohashi K, Souzaki R, Kinoshita Y, Taguchi T, Hossain MS, Ohira M, Nakamura Y, **Nakagawara A**. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma. ***Sci Rep.*** 2016 Sep 8;6:32682. doi: 10.1038/srep32682.

20. Matthay KK, Maris JM, Schleiermacher G, **Nakagawara A**, Mackall CL, Diller L, Weiss WA. NEUROBLASTOMA. ***Nat. Rev. Dis. Primers***, 2016 Nov 10;2:16078. doi: 10.1038/nrdp.2016.78.